A Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Solid Tumors Resistant or Refractory to Standard Treatments
Latest Information Update: 27 Apr 2023
At a glance
- Drugs CAL056 mesylate (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Calgent Biotechnology
- 06 Apr 2023 Status changed from recruiting to completed.
- 17 Jan 2021 Status changed from not yet recruiting to recruiting.
- 04 Jan 2021 New trial record